Skip to Main Content

Editor’s note: A recording of the conversation is embedded below.

A new type of antibody that can attach to more than one protein target may change the way cancer is treated. Take a look at some of the entrants in a hot new field with us.


10-28-assets_Sponsored By

Featured Speakers: 

  • Irene Ghobrial, M.D., Lavine Family Chair of Preventative Cancer Therapy, professor of medicine, Dana-Farber Cancer Institute
  • Jill O’Donnell-Tormey, Ph.D., CEO and director of scientific affairs, Cancer Research Institute
  • Damian Garde, national biotech reporter, STAT (moderator)
  • Tony Polverino, Ph.D., executive vice president, early development and chief scientific officer, Zymeworks (sponsor speaker)


Create a display name to comment

This name will appear with your comment

There was an error saving your display name. Please check and try again.